Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FFBM8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,485
Award facts
- Contract value 100% obligated
- $10,484.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $10,484.64 to DMS Pharmaceutical Group Inc. for Xolair 300 mg/2 ml auto-injector units under a firm fixed-price arrangement. The award, issued on November 24, 2025, with an ultimate completion date of December 16, 2025, carries no set-aside designation and will be performed at the contractor's Park Ridge, Illinois location. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was selected to supply this biologic immunosuppressant medication to support Department of Defense medical supply requirements.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion government-wide acquisition strategy. The underlying IDC, awarded on November 13, 2025, carries a $500 million ceiling and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a regional prime vendor contractor authorized to supply pharmaceuticals, biologics, and medical consumables to military healthcare facilities worldwide. The company's established performance across diverse therapeutic categories and product lines demonstrates its capability to fulfill specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FFBM8?
SPE2DR26FFBM8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 24, 2025.
How much is contract SPE2DR26FFBM8 worth?
The government has obligated $10,485 on SPE2DR26FFBM8.
Is contract SPE2DR26FFBM8 an order under another contract?
Yes. SPE2DR26FFBM8 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBM8 competed?
The extent of competition for SPE2DR26FFBM8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award